IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, December 2023

Mavacamten: A Breakthrough Drug for Hypertrophic Cardiomyopathy

Kalpesh Chotu Prajapati, Walunj Kajal Bhaskar, Chanchal Goraksha Varhadi, Satyajeet Dadabhau Walunj, Omkar Santosh Bhujbhal
Department of Pharmaceutical Analysis
Samarth Institute of Pharmacy, Belhe, Maharashtra, India
drxkalpesh24@gmail.com

Abstract: *Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder marked by the abnormal thickening of the heart muscle, leading to impaired cardiac function and increased risk of life-threatening complications. Mavacamten, a groundbreaking medication, has emerged as a promising therapeutic option for managing HCM. This abstract summarizes the key aspects of Mavacamten*
Mechanism of Action: Mavacamten is a myosin inhibitor that targets the fundamental mechanical dysfunction underlying HCM. By reducing the hypercontractility of cardiac muscle fibers, Mavacamten alleviates the obstruction of blood flow from the left ventricle and improves diastolic function.
Clinical Efficacy: Clinical trials have demonstrated the efficacy of Mavacamten in reducing symptoms and improving exercise capacity in individuals with HCM. It has shown the ability to mitigate left ventricular outflow tract obstruction, thereby enhancing the quality of life for affected patients.
Safety Profile: Mavacamten has exhibited a favorable safety profile, with side effects generally being mild and manageable. Adverse events primarily include musculoskeletal issues, such as muscle spasms and pain, but severe complications are infrequent.
Future Implications: Mavacamten represents a significant advancement in the treatment of HCM. Its approval and adoption in clinical practice offer a targeted approach to manage the disease's underlying pathophysiology, potentially reducing the need for invasive procedures or cardiac surgery..

Keywords: Mavacamten, Hypertrophic Cardiomyopathy, Myosin Inhibitor, Drug Mechanism, Clinical Efficacy, Safety Profile, Treatment Review

REFERENCES

[1]. Bello J. Pellegrini M.V.(2023),Mavacamten , https://www.ncbi.nlm.nih.gov/books/NBK582152/
[2]. SR Ommen, C Semsarian, P Spirito, I Olivotto(2014), Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine,https://www.jacc.org/doi/abs/10.1016/j.jacc.2014.05.003
[3]. Susan J. Keam,(2022), Mavacamten: first approval https://link.springer.com/article/10.1007/s40265-022-01739-7
[4]. Michael A. Geeves(2016), Review: The ATPase mechanism of myosin and actomyosin,https://onlinelibrary.wiley.com/doi/abs/10.1002/bip.22853
[5]. SJ Rao, B Forst, AK Kanwal, A Kanwal, WS Aronow, SS Naidu(2023), Cardiac myosin inhibitors for hypertrophic cardiomyopathy: shedding light on their clinical potential. https://www.tandfonline.com/doi/full/10.1080/13543784.2023.2166825
[6]. Mohammad Saber Tehrani, Mohammad Taghi Vardini, Parviz Abroomand Azar, Syed waqif Husain volume5(2010), Metaprolol : Activation of PPAR-γ prevents TERT-mediated pulmonary vascular remodeling in MCT-induced pulmonary hypertension https://www.sciencedirect.com/science/article/pii/S1452398123152692
[7]. C Chuang, S Collibee, L Ashcraft, W Wang(2021) , Discovery of Aficamten (CK-274) https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c01290

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.301
Volume 3, Issue 1, December 2023

[8]. Olivotto, I., Oręziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., García-Pavía, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A. T., Kubánek, M., Wojakowski, W., Jensen, M. K., Gimeno-Blanes, J. R., Afshar, K., Myers, J., Hegde, S. M., Solomon, S. D., Sehnert, A. J., . . . Yamani, M. H. (2020). Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 396(10253), 759–769. https://doi.org/10.1016/s0140-6736(20)31792-x

[9]. Heitner, S. B., Jacoby, D., Lester, S. J., Owens, A. T., Wang, A., Zhang, D., Lambing, J. L., Lee, J., Semigran, M. J., & Sehnert, A. J. (2019). Mavacamten treatment for Obstructive Hypertrophic cardiomyopathy. Annals of Internal Medicine, 170(11), 741. https://doi.org/10.7326/m18-3016

[10]. Rohde, J. A., Roopnarine, O., Thomas, D. D., & Muretta, J. M. (2018). Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin. Proceedings of the National Academy of Sciences of the United States of America, 115(32). https://doi.org/10.1073/pnas.1720342115

[11]. Mamidi, R., Li, J., Doh, C. Y., Verma, S., & Stelzer, J. E. (2018). Impact of the myosin modulator Mavacamten on force generation and Cross-Bridge behavior in a murine model of hypercontractility. Journal of the American Heart Association, 7(17). https://doi.org/10.1161/jaha.118.009627

[12]. Papadakis, M., Basu, J., & Sharma, S. (2020). Mavacamten: treatment aspirations in hypertrophic cardiomyopathy. The Lancet, 396(10253), 736–737. https://doi.org/10.1016/s0140-6736(20)31793-1

[13]. Capilupi, M. J., & Frishman, W. H. (2022, December 2). Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy. Cardiology in Review, 31(1), 45–51. https://doi.org/10.1097/crd.0000000000000433

[14]. Chin, A. C., & Day, S. M. (2022, July 11). Myosin modulators move forward with FDA approval of mavacamten. Nature Cardiovascular Research, 1(7), 595–596. https://doi.org/10.1038/s44161-022-00093-x

[15]. Gras, J. (2021). Mavacamten. Allosteric modulator of cardiac myosin, Treatment of hypertrophic cardiomyopathy, Treatment of heart failure with preserved ejection fraction. Drugs of the Future, 46(6), 443. https://doi.org/10.1358/dof.2021.46.6.3273821